Rigosertib and Cholangiocarcinoma: A Cell Cycle Affair

Rigosertib is multi-kinase inhibitor that could represent an interesting therapeutic option for non-resectable patients with cholangiocarcinoma, a very aggressive hepatic cancer with limited effective treatments. The Western blotting technique was used to evaluate alterations in the expression of pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Malacrida, Alessio, Cavaletti, Guido, Miloso, Mariarosaria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745771/
https://www.ncbi.nlm.nih.gov/pubmed/35008638
http://dx.doi.org/10.3390/ijms23010213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745771/
https://www.ncbi.nlm.nih.gov/pubmed/35008638
http://dx.doi.org/10.3390/ijms23010213

Ejemplares similares